Skip to main content
SpringerLink
Log in

Phosphatbinder, Vitamin D, Cinacalcet

Therapierichtlinien

Phosphate binders, vitamin D, cinacalcet

Therapeutic guidelines

  • Leitthema
  • Published:
Der Nephrologe Aims and scope

Zusammenfassung

Zukünftige Therapierichtlinien hinsichtlich des Knochen- und Calcium-Phosphat-Stoffwechsels bei der Niereninsuffizienz müssen sowohl die kardiovaskulären als auch die ossären Manifestationen des sekundären Hyperparathyreoidismus und der Dysregulationen im Calcium- und Phosphat-Haushalt berücksichtigen. Die differenzierte Therapie mit Phosphatbindern, aktiven Vitamin-D-Analoga bzw. Calcimimetika muss dabei jeweils dem einzelnen Patienten individualisiert angepasst werden. Hier spielen Komorbidität, Risikoprofil und auch gesundheitsökonomische Aspekte bei der Entscheidungsfindung eine wichtige Rolle.

Abstract

In the future, clinical treatment recommendations with regard to chronic kidney disease mineral and bone disorder (CKD-MBD) will have to consider cardiovascular as well as bone manifestations of secondary hyperparathyroidism and dysregulation of calcium and phosphate homeostasis. Differential therapy, including phosphate binders, active vitamin D analogues, and calcimimetics, must be tailored to the individual patient. Comorbidities, risk profiles, and also health-economic aspects will be important for guiding decision making.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607–617

    Article  PubMed  CAS  Google Scholar 

  2. Block GA, Klassen PS, Lazarus JM et al. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208–2218

    Article  PubMed  CAS  Google Scholar 

  3. Young EW, Albert JM, Satayathum S et al. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179–1187

    Article  PubMed  CAS  Google Scholar 

  4. Slinin Y, Foley RN, Collins A (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788–1793

    Article  PubMed  CAS  Google Scholar 

  5. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771–780

    Article  PubMed  CAS  Google Scholar 

  6. Eknoyan G, Levin A, Levin N (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (Suppl 3) 42: S1–S201

    Article  Google Scholar 

  7. Jono S, McKee MD, Murry CE et al. (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10–E17

    PubMed  CAS  Google Scholar 

  8. Giachelli CM (2004) Vascular calcification mechanisms. J Am Soc Nephrol 15: 2959–2964

    Article  PubMed  Google Scholar 

  9. Moe SM, Drüeke TB (2004) Management of secondary hyperparathyreoidism: The importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus and calcium-phosphorus-product. Am J Nephrol 23: 369–379

    Article  Google Scholar 

  10. Levin A, Bakris GL, Molitch M et al. (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71: 31–38

    Article  PubMed  CAS  Google Scholar 

  11. Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18: 1637–1347

    Article  PubMed  CAS  Google Scholar 

  12. Souberbielle JC, Boutten A, Carlier MC et al. (2006) Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 70: 345–350

    Article  PubMed  CAS  Google Scholar 

  13. Ferreira A et al. (2008) J Am Soc Nephrol JASN

  14. Goodman WG, Veldhuis JD, Belin TR et al. (1997) Suppressive effect of calcium on parathyroid hormone release in adynamic renal osteodystrophy and secondary hyperparathyreoidsm. Kidney Int 51: 1590–1595

    Article  PubMed  CAS  Google Scholar 

  15. Sherrad DJ, Hercz G, Pei Y et al. (1993) The spectrum of bone disease in end-stage renal failure – An evolving disorder. Kidney Int 43: 436–442

    Article  Google Scholar 

  16. Ketteler M, Schlieper G, Floege J (2006) Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47: 1027–1034

    Article  PubMed  CAS  Google Scholar 

  17. Vliegenthart R, Oudkerk M, Song B et al. (2002) Coronary calcification detected by electron-beam computed tomography and myocardial infarction. The Rotterdam Coronary Calcification Study. Eur Heart J 23: 1596–1603

    Article  PubMed  CAS  Google Scholar 

  18. Vliegenthart R, Hollander M, Breteler MM et al. (2002) Stroke is associated with coronary calcification as detected by electron-beam CT: the Rotterdam Coronary Calcification Study. Stroke 33: 462–465

    Article  PubMed  Google Scholar 

  19. Block GA, Raggi P, Bellasi A et al. (2007) Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438–441

    Article  PubMed  CAS  Google Scholar 

  20. Shao JS, Cai J, Towler DA (2006) Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol 26: 1423–1430

    Article  PubMed  CAS  Google Scholar 

  21. Moe S, Drüeke T, Cunningham J et al. Kidney Disease: Improving Global Outcomes (KDIGO) (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945–1953

    Article  PubMed  CAS  Google Scholar 

  22. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis (Suppl 3) 32: S112–S119

    Article  Google Scholar 

  23. Goodman WG, Goldin J, Kuizon BD et al. (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478–1483

    Article  PubMed  CAS  Google Scholar 

  24. Splendiani G, Morosetti M, Manni M et al. (2004) Cardiac calcium evaluation in hemodialysis patients with multisection spiral computed tomography. Int J Artif Organs 27: 759–765

    PubMed  CAS  Google Scholar 

  25. Teng M, Wolf M, Ofsthun MN et al. (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16: 1115–1125

    Article  PubMed  CAS  Google Scholar 

  26. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71: 356–363

    Article  PubMed  CAS  Google Scholar 

  27. Haffner D, Hocher B, Müller D et al. (2005) Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 23: 1067–1075

    Article  PubMed  CAS  Google Scholar 

  28. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245–252

    Article  PubMed  CAS  Google Scholar 

  29. Block GA, Spiegel DM, Ehrlich J et al. (2005) Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815–1824

    Article  PubMed  CAS  Google Scholar 

  30. Ketteler M, Biggar P (2008) After several years of witchhunting: Can calcium-based phosphate binding be released on probation? Nephrol Dial Transplant 23: 17–19

    Article  PubMed  Google Scholar 

  31. Russo D, Miranda I, Ruocco C et al. (2007) The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int: Epub ahead of print

    Google Scholar 

  32. Phan O et al. (2007) Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoe/) mice with chronic renal failure. Nephrol Dial Transplant 19 (Epub ahead of print)

  33. Reynolds JL, Joannides AJ, Skepper JN et al. (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857–2867

    Article  PubMed  CAS  Google Scholar 

  34. Suki WN, Zabaneh R, Cangiano JL et al. (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130–1137

    Article  PubMed  CAS  Google Scholar 

  35. Ferramosca E, Burke S, Chasan-Taber S et al. (2005) Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149: 820–825

    Article  PubMed  CAS  Google Scholar 

  36. Garg JP, Chasan-Taber S, Blair A et al. (2005) Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52: 290–295

    Article  PubMed  CAS  Google Scholar 

  37. Phan O, Ivanovski O, Nguyen-Khoa T et al. (2005) Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112: 2875–2882

    Article  PubMed  CAS  Google Scholar 

  38. D’Haese PC, Spasovski GB, Sikole A et al. (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 63: S73–S78

    Article  Google Scholar 

  39. Lacour B, Lucas A, Auchere D et al. (2005) Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 67: 1062–1069

    Article  PubMed  CAS  Google Scholar 

  40. Slatopolsky E, Liapis H, Finch J (2005) Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68: 2809–2813

    Article  PubMed  CAS  Google Scholar 

  41. Yang Z, Schryvers D, Roels F et al. (2006) Demonstration of lanthanum in liver cells by energy-dispersive X-ray spectroscopy, electron energy loss spectroscopy and high-resolution transmission electron microscopy. J Microsc 223: 133–139

    Article  PubMed  CAS  Google Scholar 

  42. Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281

    Article  PubMed  CAS  Google Scholar 

  43. Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15: 2579–2585

    Article  PubMed  CAS  Google Scholar 

  44. Andress DL (2006) Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 69: 33–43

    Article  PubMed  CAS  Google Scholar 

  45. Uhlig K, Macleod A, Craig J et al. (2006) Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70: 2058–2065

    PubMed  CAS  Google Scholar 

  46. Slatopolsky E, Cozzolino M, Finch JL (2002) Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 62: 1277–1284

    Article  PubMed  CAS  Google Scholar 

  47. Sprague SM, Llach F, Amdahl M et al. (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63: 1483–1490

    Article  PubMed  CAS  Google Scholar 

  48. Teng M, Wolf M, Lowrie E et al. (2003) Survival of patients undergoing dialysis with paricalcitol and calcitriol therapy. N Engl J Med 349: 446–456

    Article  PubMed  CAS  Google Scholar 

  49. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E (2007) Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72: 709–715

    Article  PubMed  CAS  Google Scholar 

  50. Zierold C, Mings JA, Deluca HF (2006) 19nor-1,25-dihydroxyvitamin D2 specifically induces CYP3A9 in rat intestine more strongly than 1,25-dihydroxyvitamin D3 in vivo and in vitro. Mol Pharmacol 69: 1740–1747

    Article  PubMed  CAS  Google Scholar 

  51. Wu-Wong JR, Nakane M, Ma J et al. (2007) VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem 100: 1395–1405

    Article  PubMed  CAS  Google Scholar 

  52. Block GA, Martin KJ, Francisco AL de et al. (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516–1525

    Article  PubMed  CAS  Google Scholar 

  53. Cunningham J, Danese M, Olson K et al. (2005) Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793–1800

    Article  PubMed  CAS  Google Scholar 

  54. Colloton M, Shatzen E, Miller G et al. (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67: 467–476

    Article  PubMed  CAS  Google Scholar 

  55. Lopez I, Aguilera-Tejero E, Mendoza FJ et al. (2006) Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17: 795–804

    Article  PubMed  CAS  Google Scholar 

  56. Srinivas TR, Schold JD, Womer KL et al. (2006) Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 1: 323–326

    Article  PubMed  CAS  Google Scholar 

  57. Serra AL, Savoca R, Huber AR et al. (2007) Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 22: 577–583

    Article  PubMed  CAS  Google Scholar 

  58. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098

    Article  PubMed  CAS  Google Scholar 

  59. Drüeke TB, Locatelli F, Clyne N et al. CREATE Investigators (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084

    Article  PubMed  Google Scholar 

Download references

Interessenkonflik

Der Autor erhielt Vortrags- und Beraterhonorare bzw. Forschungsmittel von den Firmen Abbott, Amgen, Fresenius, Genzyme und Shire.

Author information

Authors and Affiliations

  1. Medizinische Klinik III: Nephrologie, Klinikum Coburg gGmbH, Ketschendorfer Str. 33, 96450, Coburg, Deutschland

    M. Ketteler

Authors
  1. M. Ketteler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Ketteler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ketteler, M. Phosphatbinder, Vitamin D, Cinacalcet. Nephrologe 3, 96–107 (2008). https://doi.org/10.1007/s11560-007-0131-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11560-007-0131-x

Schlüsselwörter

Keywords

Search

Navigation